Journal: Translational Oncology

Article Title: HER2 as a potential therapeutic target on quiescent prostate cancer cells

doi: 10.1016/j.tranon.2023.101642

Figure Lengend Snippet: Impact of T-DM1 treatment on metastasis free survival in a prostate cancer left ventricle injection xenograft model. (A) Experimental design for the in vivo experiment. GFP/luciferase-expressing PC3 cells were injected into male SCID mice by left ventricle intracardiac (i.c.) injection. Human IgG (15 mg/kg) or T-DM1 (15 mg/kg) were injected by intraperitoneal (i.p.) injection every 3 days until 12 days after tumor injection IgG: n = 12. T-DM1: n = 14. (B) Kaplan-Meier analysis of time to formation of metastases visible by bioluminescence imaging or death. (C) Representative bioluminescence images of control mice (human IgG injected) and T-DM1 treated mice 124 days after tumor injection. (D) Antibody dependent cellular cytotoxicity (ADCC) assays using flow cytometry. PC3 cells were labeled with DiD for subsequent identification, and were treated with T-DM1 before addition of splenocytes from SCID mice. PC3 cells were identified as DiD positive and non-viable cells were identified as positive for DAPI. (E) Dead PC3 cells (%) quantified from data in panel (D) Data represent mean ± S.D. (N=3).

Article Snippet: Monoclonal mouse IgG2B (R&D systems, Cat #: IC0041V) was used as isotype control.

Techniques: Injection, In Vivo, Luciferase, Expressing, Imaging, Control, Flow Cytometry, Labeling